Biotech News 18 October 2025

Alexandria Real Estate Equities (ARE) Stock Plummets to 52-Week Low After Q3 Miss – Can the Biotech REIT Rebound?

Stock Nosedives on Earnings News Pasadena, Calif., Oct. 28, 2025 – Alexandria Real Estate Equities (NYSE: ARE) saw its stock price collapse to a new 52-week low in Tuesday’s trading, as disappointing quarterly

28 October 2025

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Bottom Line: Avidity Biosciences’ stock is set to explode higher on Novartis’s $12 billion buyout, capping off a dramatic run fueled by breakthrough science and takeover buzz. The high-premium deal underscores the

26 October 2025

Biotech · Mergers & Acquisitions · Pharmaceuticals · Rare Diseases · Stock Market

Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next?

Theriva’s Stock Swing: In mid-October, Theriva’s Nasdaq-traded shares spiked on news of clinical success. On Oct. 15 the stock jumped from roughly $0.44 to $0.84 intraday ts2.tech, an increase of about 92%.

24 October 2025

Biotech · Cancer Research · Clinical Trials · Investing · NASDAQ:TOVX · Stock Market

Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Key Facts: – Neuphoria (Nasdaq: NEUP) shares plunged ~67% in after-hours trading on Oct 20 when its lead drug BNC210 failed a Phase 3 SAD trial investing.com. The AFFIRM-1 trial missed both

24 October 2025

Biotech · Clinical Trials · Investing · Mental Health · NASDAQ:NEUP · Stock Market

Armata (ARMP) Stock Surges 150% After Breakthrough Bacteriophage Trial Results

Armata’s stock performance this week has been nothing short of dramatic. Prior to Oct. 22, ARMP had been trading in the low-$3 range (for example, it closed around $3.41 on Oct. 16

22 October 2025

Biotech · Investing · Market News · Pharma · Stocks

Thermo Fisher Stock Skyrockets – Biotech Boom & Big Deals Fuel Rally, Analysts Eye $650

Stock Performance and Sector Rally Thermo Fisher’s stock price has surged in recent weeks on renewed investor optimism. After a slow start to 2025 (even a ~10% year-over-year dip early in the

22 October 2025

Analyst Insights · Biotech · Financial News · Investing · NYSE:TMO · Stock Market

Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Stock Soars on Major Funding News Minerva Neurosciences’ stock chart went vertical on Tuesday after the biotech announced an expansive financing deal that effectively triples the company’s market capitalization overnight marketbeat.com. In

21 October 2025

Biotech · Investment · Pharmaceuticals · Schizophrenia · Stock Market

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

IBIO Stock Price and Recent Volatility As of midday October 21, 2025, iBio’s stock (NASDAQ: IBIO) trades around $0.89 per share marketbeat.com. The price has been volatile in recent days. Last week,

21 October 2025

Analyst Ratings · Biotech · Obesity Research · Pharmaceuticals · Stock News

Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

SMMT Stock’s Wild Ride in 2025 Summit Therapeutics’ share price has been on a roller-coaster ride this year. After a steady climb through late summer, SMMT spiked above $25 intraday in mid-October,

20 October 2025

Biotech · Cancer Research · Investment News · Medical Breakthroughs · NASDAQ:SMMT · Stock Market

Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

What to Know Before Markets Open on October 20, 2025 SMMT’s Wild Stock Ride in 2025 Summit Therapeutics’ share price has experienced extreme swings this year. After a steady climb through late

19 October 2025

Biotech · Cancer Research · Investing · Medical News · NASDAQ:SMMT · Stock Market

Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Stock Surge & Analyst Reaction Atai shares exploded higher on Oct. 17, 2025. Investors bid the stock up ~17.7%, closing at roughly $6.45 ts2.tech (versus ~$5.48 offering price). In after-hours trading it

18 October 2025

Biotech · FDA Approval · Investments · NASDAQ:ATAI · Psychedelics · Stock Market

MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

Stock Soars on Catalyst News MindMed’s stock has skyrocketed in recent weeks. After languishing in the single digits, MNMD climbed above $12 in late September and spiked to $13.09 on Oct. 14,

18 October 2025

Biotech · Investing · Market News · Mental Health · NASDAQ:MNMD · Stocks

Biotech News 18 October 2025 - 28 October 2025